Rahim Shafa
Psychiatry · Natick, MANPI 1205920527
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,140 of the $46,624 with a category attached, or 79.7%. 20 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 47.2% of the total. Reporting peaked in 2019 at $38,600 and has fallen 99.4% since, to $239 in 2023. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $148.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$22K
- Alkermes, Inc.$17K
- AbbVie$5K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Sunovion Pharmaceuticals Inc.$504
- Neurocrine Biosciences, Inc.$437
- plus $1K from 14 others
What the payments were for
- Speaking & faculty fees$37,14080%
- Travel & lodging$4,0999%
- Food & beverage$5,10611%
- Education$2801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 99 | $22,008 |
| Alkermes, Inc. | 41 | $16,596 |
| AbbVie(2 entities) | 53 | $4,729 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $1,000 |
| Sunovion Pharmaceuticals Inc. | 26 | $504 |
| Neurocrine Biosciences, Inc. | 21 | $437 |
| Johnson & Johnson | 14 | $204 |
| Vanda Pharmaceuticals Inc. | 8 | $179 |
| Teva Pharmaceuticals USA, Inc. | 7 | $177 |
| Avanir Pharmaceuticals, Inc. | 8 | $177 |
| Arbor Pharmaceuticals, Inc. | 12 | $166 |
| Lundbeck LLC | 10 | $140 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $91 |
| Novartis | 4 | $88 |
| Shire North American Group Inc | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Assertio Therapeutics, Inc. | 1 | $20 |
| Kaleo, Inc. | 1 | $17 |
| Indivior Inc. | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$63,348
- ABILIFY MAINTENA$19,912
- ARISTADA INITIO$15,837
- VRAYLAR$3,965
- CAPLYTA$1,000
- INGREZZA$136
- BOTOX COSMETIC$128
- REXULTI$114
How this compares
$46,624 in reported general payments places this provider in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Other psychiatry in Natick
- Theresa CerulliNorth Andover$724K
- Andrew AldridgeMedford$407K
- Amjad BahnassiWorcester$352K
- Ximena Sanchez-SamperBoston$258K
- Robert AlexanderBelmont$170K
- George PapakostasBoston$170K
- Xiangyang LiMilford$166K
- Ernesto ZilberbergNorth Andover$141K
- Maurizio FavaBoston$120K
- Craig SurmanCambridge$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.